Suppr超能文献

相似文献

1
Past, present and future targets for immunotherapy in ovarian cancer.
Immunotherapy. 2014;6(12):1279-93. doi: 10.2217/imt.14.90.
2
The Role of the Immune System in Ovarian Cancer and Implications on Therapy.
Expert Rev Clin Immunol. 2016 Jun;12(6):681-95. doi: 10.1586/1744666X.2016.1147957. Epub 2016 Feb 15.
3
Immunotherapy in ovarian cancer.
Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7. doi: 10.1093/annonc/mdx444.
4
Emerging immunotherapies in ovarian cancer.
Discov Med. 2015 Sep;20(109):97-109.
5
Ovarian Cancer Immunotherapy: Turning up the Heat.
Int J Mol Sci. 2019 Jun 15;20(12):2927. doi: 10.3390/ijms20122927.
6
Immunotherapy in ovarian cancer.
Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15.
7
Immunotherapy for ovarian cancer: recent advances and perspectives.
Curr Opin Oncol. 2014 Sep;26(5):492-500. doi: 10.1097/CCO.0000000000000111.
8
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors.
J Immunol Res. 2015;2015:191832. doi: 10.1155/2015/191832. Epub 2015 Jul 7.
9
Immunotherapy opportunities in ovarian cancer.
Expert Rev Anticancer Ther. 2008 Feb;8(2):243-57. doi: 10.1586/14737140.8.2.243.
10
Immunotherapy for ovarian cancer: what are the targets of the future?
Future Oncol. 2015;11(9):1293-6. doi: 10.2217/fon.15.44.

引用本文的文献

5
Pan-Cancer Analysis Reveals the Potential of PLOD1 as a Prognostic and Immune Biomarker for Human Cancer.
Biomedicines. 2024 Nov 21;12(12):2653. doi: 10.3390/biomedicines12122653.
6
Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.
Clin Transl Immunology. 2024 May 23;13(5):e1512. doi: 10.1002/cti2.1512. eCollection 2024.
8
Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Biomolecules. 2023 Feb 8;13(2):326. doi: 10.3390/biom13020326.
9
10
Cisplatin increases immune activity of monocytes and cytotoxic T-cells in a murine model of epithelial ovarian cancer.
Transl Oncol. 2021 Dec;14(12):101217. doi: 10.1016/j.tranon.2021.101217. Epub 2021 Sep 14.

本文引用的文献

3
PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
PLoS One. 2014 Feb 27;9(2):e89350. doi: 10.1371/journal.pone.0089350. eCollection 2014.
4
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Cancer Immunol Res. 2014 Jan;2(1):37-49. doi: 10.1158/2326-6066.CIR-13-0126.
6
Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas.
Cell Physiol Biochem. 2014;33(1):173-84. doi: 10.1159/000356660. Epub 2014 Jan 24.
7
Trial watch: Dendritic cell-based interventions for cancer therapy.
Oncoimmunology. 2013 Oct 1;2(10):e25771. doi: 10.4161/onci.25771. Epub 2013 Jul 29.
8
Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses.
Oncoimmunology. 2013 Aug 1;2(8):e25913. doi: 10.4161/onci.25913. Epub 2013 Jul 31.
9
Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin.
J Immunol. 2013 Sep 1;191(5):2437-45. doi: 10.4049/jimmunol.1301119. Epub 2013 Jul 29.
10
Naturally circulating dendritic cells to vaccinate cancer patients.
Oncoimmunology. 2013 Mar 1;2(3):e23431. doi: 10.4161/onci.23431.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验